Stay updated with breaking news from Michaelr Bishop. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has cleared the investigational new drug application for CHM 2101, a novel CDH17-targeted CAR T-cell therapy, for the treatment of patients with gastrointestinal cancers.
Crain's Health Pulse is your source for actionable, exclusive and inside news on the health care industry.
10.11.2022 - INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meeting.Partnered with the Dunbar CAR T-Cell Program at the ...
INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce...
Hans Schreiber, MD, PhD, was recognized for his dedication and significant contributions to the promising field of cellular immunotherapy for cancer treatment.